Langhorne, Pa., - Alliqua Inc. launched its Biovance human amniotic membrane allograft product, during the Spring 2014 Symposium on Advanced Wound Care held at the Gaylord Palms Hotel and Convention Center in Orlando, Fla.
Biovance was originally developed by, and is currently being manufactured through a supply agreement with, Celgene Cellular Therapeutics (CCT), a subsidiary of Celgene Corp., to assist wound care specialists, physicians and nurses, as well as vascular, plastic and general surgeons, in the treatment of a wide variety of complex, acute, chronic, recalcitrant, full, and partial thickness wound types.
With the right to develop and market Biovance, Alliqua has entered into one of the fastest-growing areas of wound care, which involves regenerative medicine. Alliqua will commence sales of Biovance immediately following the Symposium via its team of direct sales representatives.
Perry Karsen, CEO of Celgene Cellular Therapeutics, remarked, "We have great confidence in Alliqua and its management team in bringing Biovance to patients throughout the United States."
On April 14, 2014, Celgene invested $5,000,000 in Alliqua as part of the company's previously announced private placement that resulted in gross proceeds to the company of $15 million.
David Johnson, CEO of Alliqua, said, "The SAWC meeting is the ideal venue at which to launch our Biovance product and to convey its natural benefits to the wound care community. The launch of Biovance marks a major milestone for Alliqua, representing a key application of regenerative medicine for advanced wound care and an important addition to Alliqua's wound care portfolio. We are confident that wound care specialists and their patients will be impressed with the value this human amniotic membrane allograft brings to their wound care arsenal."
Source: Alliqua Inc.